An autocrine loop between TGF-β1 and the transcription factor brachyury controls the transition of human carcinoma cells into a mesenchymal phenotype

Molecular Cancer Therapeutics

Volumn 12, Issue 9, 2013, Pages 1805-1815

  Larocca, Cecilia ^a,b   Cohen, Joseph R ^a   Fernando, Romaine I ^a   Huang, Bruce ^a   Hamilton, Duane H ^a   Palena, Claudia ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b HHMINIH Research Scholar   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 (5 CHLORO 2 FLUOROPHENYL) 4 (4 PYRIDINYLAMINO)PTERIDINE; BRACHYURY; CISPLATIN; DOCETAXEL; MESSENGER RNA; NAVELBINE; T BOX TRANSCRIPTION FACTOR; TRANSFORMING GROWTH FACTOR BETA1; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTOCRINE EFFECT; CARCINOMA CELL; CELL TRANSFORMATION; CHEMOSENSITIVITY; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; EPITHELIAL MESENCHYMAL TRANSITION; FEEDBACK SYSTEM; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CELL LINE, TUMOR; CISPLATIN; DRUG EVALUATION, PRECLINICAL; DRUG RESISTANCE, NEOPLASM; EPITHELIAL-MESENCHYMAL TRANSITION; FEEDBACK, PHYSIOLOGICAL; FETAL PROTEINS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; NEOPLASMS; PHENOTYPE; PTERIDINES; RECEPTORS, TRANSFORMING GROWTH FACTOR BETA; SIGNAL TRANSDUCTION; T-BOX DOMAIN PROTEINS; TRANSFORMING GROWTH FACTOR BETA1; VINBLASTINE;

EID: 84884524473     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-12-1007     Document Type: Article

References (49)

1. Thiery JP. Epithelial-mesenchymal transitions in tumour progression. Nat Rev Cancer 2002;2:442-54.
2. Kalluri R, Weinberg RA. The basics of epithelial-mesenchymal transition. J Clin Invest 2009;119:1420-8.
3. Acloque H, Adams MS, Fishwick K, Bronner-Fraser M, Nieto M.A. Epithelial-mesenchymal transitions: the importance of changing cell state in development and disease. J Clin Invest 2009;119:1438-49.
4. Nieto MA. The ins and outs of the epithelial to mesenchymal transition in health and disease. Annu Rev Cell Dev Biol 2011;27:347-76.
5. Kajiyama H, Shibata K, Terauchi M, Yamashita M, Ino K, Nawa A, et al. Chemoresistance to paclitaxel induces epithelial-mesenchymal transition and enhances metastatic potential for epithelial ovarian carcinoma cells. Int J Oncol 2007;31:277-83.
6. Kurrey NK, Jalgaonkar SP, Joglekar AV, Ghanate AD, Chaskar PD, Doiphode RY, et al. Snail and slug mediate radioresistance and chemoresistance by antagonizing p53-mediated apoptosis and acquiring a stem-like phenotype in ovarian cancer cells. Stem Cells 2009;27:2059-68.
7. Mani SA, Guo W, Liao MJ, Eaton EN, Ayyanan A, Zhou AY, et al. The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell 2008;133:704-15.
8. Polyak K, Weinberg RA. Transitions between epithelial and mesenchymal states: acquisition of malignant and stem cell traits. Nat Rev Cancer 2009;9:265-73.
9. Singh A, Settleman J. EMT, cancer stem cells and drug resistance: an emerging axis of evil in the war on cancer. Oncogene 2010;29: 4741-51.
10. Palena C, Fernando RI, Litzinger MT, Hamilton DH, Huang B, Schlom J. Strategies to target molecules that control the acquisition of a mesenchymal- like phenotype by carcinoma cells. Exp BiolMed(Maywood) 2011;236:537-45.
11. Yang J, Mani SA, Donaher JL, Ramaswamy S, Itzykson RA, Come C, et al. Twist, a master regulator of morphogenesis, plays an essential role in tumor metastasis. Cell 2004;117:927-39.
12. Carver EA, Jiang R, Lan Y, Oram KF, Gridley T. The mouse snail gene encodes a key regulator of the epithelial-mesenchymal transition. Mol Cell Biol 2001;21:8184-8.
13. Nieto MA, Sargent MG, Wilkinson DG, Cooke J.Control of cell behavior during vertebrate development by Slug, a zinc finger gene. Science 1994;264:835-9.
14. Guaita S, Puig I, Franci C, Garrido M, Dominguez D, Batlle E, et al. Snail induction of epithelial to mesenchymal transition in tumor cells is accompanied by MUC1 repression and ZEB1 expression. J Biol Chem 2002;277:39209-16.
15. Vandewalle C, Comijn J, De Craene B, Vermassen P, Bruyneel E, Andersen H, et al. SIP1/ZEB2 induces EMT by repressing genes of different epithelial cell-cell junctions. Nucleic Acids Res 2005;33:6566-78.
16. Herrmann BG, Labeit S, Poustka A, King TR, Lehrach H. Cloning of the T gene required in mesoderm formation in the mouse. Nature 1990; 343:617-22.
17. Kispert A, Hermann BG. The Brachyury gene encodes a novel DNA binding protein. EMBO J 1993;12:4898-9.
18. EdwardsYH, Putt W, Lekoape KM, Stott D, Fox M, Hopkinson DA, et al. The human homolog T of the mouse T(Brachyury) gene; genestructure, cDNA sequence, and assignment to chromosome 6q27. Genome Res 1996;6:226-33.
19. Palena C, Polev DE, Tsang KY, Fernando RI, Litzinger M, Krukovskaya LL, et al. The human T-box mesodermal transcription factor Brachyury is a candidate target for T-cell-mediated cancer immunotherapy. Clin Cancer Res 2007;13:2471-8.
20. Hamilton DH, Litzinger MT, Fernando RI, Huang B, Palena C. Cancer vaccines targeting the epithelial-mesenchymal transition: tissue distribution of brachyury and other drivers of the mesenchymal-like phenotype of carcinomas. Semin Oncol 2012;39:358-66.
21. Roselli M, Fernando RI, Guadagni F, Spila A, Alessandroni J, Palmirotta R, et al. Brachyury, a driver of the epithelial-mesenchymal transition, is overexpressed in human lung tumors: an opportunity for novel interventions against lung cancer. Clin Cancer Res 2012;18:3868-79.
22. Fernando RI, Litzinger M, Trono P, Hamilton DH, Schlom J, Palena C. The T-box transcription factor Brachyury promotes epithelial-mesenchymal transition in human tumor cells. J Clin Invest 2010;120:533-44.
23. Fernando RI, Castillo MD, Litzinger M, Hamilton DH, Palena C. IL-8 signaling plays a critical role in the epithelial-mesenchymal transition of human carcinoma cells. Cancer Res 2011;71:5296-306.
24. ClinicalTrials.gov, Open label study to evaluate the safety and tolerability of GI-6301 a vaccine consisting of whole heat-killed recombitant yeast genetically modified to express brachyury protein in adults with Solid Tumors [updated 2013 May 17; cited 2013 July 11]. Available from: www.clinicaltrials.gov/ct2/show/NCT01519817.
25. Roberts AB, Wakefield LM. The two faces of transforming growth factor beta in carcinogenesis. Proc Natl Acad Sci U S A 2003;100:8621-3.
26. Massague J, Blain SW, Lo RS. TGFbeta signaling in growth control, cancer, and heritable disorders. Cell 2000;103:295-309.
27. Derynck R, Akhurst RJ. Differentiation plasticity regulated by TGF-βeta family proteins in development and disease.NatCellBiol 2007;9:1000-4.
28. Bierie B, Moses HL. Tumour microenvironment: TGFbeta: the molecular Jekyll and Hyde of cancer. Nat Rev Cancer 2006;6:506-20.
29. Miettinen PJ, Ebner R, Lopez AR, Derynck R. TGF-βeta induced transdifferentiation of mammary epithelial cells to mesenchymal cells: involvement of type I receptors. J Cell Biol 1994;127:2021-36.
30. Tang B, Vu M, Booker T, Santner SJ, Miller FR, Anver MR, et al. TGFbeta switches from tumor suppressor to prometastatic factor in a model of breast cancer progression. J Clin Invest 2003;112:1116-24.
31. Shi Y, Massague J. Mechanisms of TGF-βeta signaling from cell membrane to the nucleus. Cell 2003;113:685-700.
32. Massague J. TGFbeta in cancer. Cell 2008;134:215-30.
33. Thuault S, Valcourt U, Petersen M, Manfioletti G, Heldin CH, Moustakas A. Transforming growth factor-beta employs HMGA2 to elicit epithelial-mesenchymal transition. J Cell Biol 2006;174:175-83.
34. Sledz CA, Holko M, de Veer MJ, Silverman RH, Williams BR. Activation of the interferon system by short-interfering RNAs. Nat Cell Biol 2003;5:834-9.
35. Hilbig A, Oettle H. Transforming growth factor beta in pancreatic cancer. Curr Pharm Biotechnol 2011;12:2158-64.
36. Padua D, Massague J. Roles of TGFbeta in metastasis. Cell Res 2009;19:89-102.
37. Wendt MK, Tian M, Schiemann WP. Deconstructing the mechanisms and consequences of TGF-βeta-induced EMT during cancer progression. Cell Tissue Res 2012;347:85-101.
38. Park HY, Wakefield LM, Mamura M. Regulation of tumor immune surveillance and tumor immune subversion by TGF-βeta. Immune Netw 2009;9:122-6.
39. Pennison M, Pasche B. Targeting transforming growth factor-beta signaling. Curr Opin Oncol 2007;19:579-85.
40. Korpal M, Kang Y. Targeting the transforming growth factor-beta signalling pathway in metastatic cancer. Eur J Cancer 2010;46: 1232-40.
41. Javelaud D, Pierrat MJ, Mauviel A. Crosstalk between TGF-βeta and hedgehog signaling in cancer. FEBS Lett 2012;586:2016-25.
42. Taube JH, Herschkowitz JI, Komurov K, Zhou AY, Gupta S, Yang J, et al. Core epithelial-to-mesenchymal transition interactome geneexpression signature is associated with claudin-low and metaplastic breast cancer subtypes. Proc Natl Acad Sci U S A 2010;107: 15449-54.
43. Dhasarathy A, Phadke D, Mav D, Shah RR, Wade PA. The transcription factors Snail and Slug activate the transforming growth factor-beta signaling pathway in breast cancer. PLoS ONE 2011;6: e26514.
44. Latinkic BV, Umbhauer M, Neal KA, Lerchner W, Smith JC, Cunliffe V. The Xenopus Brachyury promoter is activated by FGF and low concentrations of activin and suppressed by high concentrations of activin and by paired-type homeodomain proteins. Genes Dev 1997; 11:3265-76.
45. Dyson S, Gurdon JB. The interpretation of position in a morphogen gradient as revealed by occupancy of activin receptors. Cell 1998;93: 557-68.
46. Scheel C, Eaton EN, Li SH, Chaffer CL, Reinhardt F, Kah KJ, et al. Paracrine and autocrine signals induce and maintain mesenchymal and stem cell states in the breast. Cell 2011;145:926-40.
47. Gregory PA, Bracken CP, Smith E, Bert AG, Wright JA, Roslan S, et al. An autocrine TGF-βeta/ZEB/miR-200 signaling network regulates establishment and maintenance of epithelial-mesenchymal transition. Mol Biol Cell 2011;22:1686-98.
48. Shipitsin M, Campbell LL, Argani P, Weremowicz S, Bloushtain-Qimron N, Yao J, et al. Molecular definition of breast tumor heterogeneity. Cancer Cell 2007;11:259-73.
49. Huang B, Cohen JR, Fernando RI, Hamilton DH, Litzinger MT, Hodge JW, et al. The embryonic transcription factor Brachyury blocks cell cycle progression and mediates tumor resistance to conventional antitumor therapies. Cell Death Dis 2013;4:e682.